We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Nanosensing Technologies Developed for Exosome Detection and Profiling

By LabMedica International staff writers
Posted on 20 Nov 2019
Image: The nano-plasmonic exosome (nPLEX) sensor (Photo courtesy of Massachusetts General Hospital).
Image: The nano-plasmonic exosome (nPLEX) sensor (Photo courtesy of Massachusetts General Hospital).
Exosomes are extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells. Liquid biopsy technologies have been developed to do high-throughput exosome protein profiling and point-of-care (POC) exosome analysis.

The aim is to develop multiplexed assay systems to streamline the analysis of exosomes and evaluate their clinical utility for cancer management, both as diagnostic tools and to predict disease recurrence. Nanoplasmonic sensors are fabricated to accommodate at most one exosome and individually imaged in real time, enabling the label-free recording of digital responses in a highly multiplexed geometry.

Scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues developed the nano-plasmonic exosome (nPLEX) sensor, in routine use at MGH, which detects exosome protein levels based on “spectral shifts” (intensity changes) of light through thousands of optimally spaced 200-nanometer (nm) holes. Antibodies against cancer biomarkers get immobilized on the nanopores for capture.

Nanoholes on the sensor are gold and exosomes are labeled by gold nanoparticles for signal amplification. Gold has proven to have the best chemical stability for this type of assay. The device is being manufactured on a glass-based substrate, as silicon wafers proved to be too fragile. The iMEX (integrated magnetic-electrochemical exosome) device, meanwhile, integrates vesicle isolation and detection in a single platform. Target-specific exosomes first get enriched through immunomagnetic selection, for high detection sensitivity. The sensors can be miniaturized and expanded for parallel measurements.

The nPLEX has demonstrated good accuracy and 100 times greater sensitivity than the commonly used enzyme-linked immunosorbent assay (ELISA) and able to detect as few as 3,000 exosomes. The team has also come up with a protein signature for pancreatic ductal adenocarcinoma (PDAC) that is powerful enough for diagnostic purposes, a combination of EGFR (epidermal growth factor receptor), EpCAM, MUC1, GPC1 and WNT2. As demonstrated in a prospective study involving more than 100 patients and age-matched controls, as the tumors shrink the biomarker combination gets lower and lower.

The scientists have also used nPLEX technology to show how exosome protein expression of cancer cells changes with drug treatment. Discovery of these unique, drug-dependent protein signatures suggests the exosome screening assay will be a potentially powerful molecular screening tool. Hyungsoon Im, PhD, an assistant professor of radiology and a senior author of the study, said, “The screening assay could be incorporated into point–of–care (POC) instruments for more rigorous testing of different drugs in different settings. The study was presented at the 2019 Next Generation Dx Summit held August 20-22, 2019 in Washington, DC, USA.

Related Links:
Massachusetts General Hospital

Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
PURITAN MEDICAL